lamivudine · Tablet

What changed in the last 90 days

Every detected change for lamivudine, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.

Same drug class

Other molecules FDA puts in Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

• abacavir sulfate, dolutegravir sodium, lamivudine· 1 maker
• dolutegravir sodium and lamivudine· 1 maker
• elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide· 1 maker
• emtricitabine and tenofovir alafenamide· 1 maker
• emtricitabine, rilpivirine and tenofovir disoproxil fumarate· 1 maker
• emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide· 1 maker
• emtricitabine, rilpivirine, tenofovir disoproxil fumarate· 1 maker
• emtricitabine/tdf· 1 maker
• entecavir anhydrous· 1 maker
• lamivudine and tenofovir disoproxil fumarate· 1 maker
• tenofovir alafenamide· 1 maker
• tenofovir disoproxil fumarate tablets· 1 maker

Common questions

Is Lamivudine in shortage right now?

No. FDA does not currently list Lamivudine in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.

Who makes Lamivudine?

25 companies have marketed Lamivudine in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.

What does Lamivudine cost?

The typical pharmacy pays about $0.4887 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.